Recent from talks
Dennis S. Charney
Knowledge base stats:
Talk channels stats:
Members stats:
Dennis S. Charney
Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #49 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 218 with 173,960 citations across 887 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.
Until July 2025 he was a professor of psychiatry, professor of neuroscience and professor of pharmacology and systems therapeutics at Icahn School of Medicine at Mount Sinai in New York City.
In 2007, he became the Dean of the School and Executive Vice President for Academic Affairs of what was then known as the Mount Sinai Medical Center. In 2013, he was named President of Academic Affairs for the Mount Sinai Health System. He retired as Dean in 2025.
Charney graduated from medical school at Penn State in 1977 and completed his residency in Psychiatry at Yale School of Medicine. A fellowship in Biological Psychiatry was completed at the Connecticut Medical Health Center.
Charney became the dean of research at Mount Sinai School of Medicine in 2004, later becoming the dean for academic and scientific affairs, then succeeding Kenneth L. Davis as dean of the Icahn School of Medicine at Mount Sinai in 2007, retiring in 2025. He was elected to the Institute of Medicine in 2000.
Charney led the Mood and Anxiety Research Program at the National Institute of Mental Health and earlier was on the faculty in the department of psychiatry at Yale Medical School.
According to published works, Charney's research is centered around various fields such as psychiatry, anesthesia, clinical psychology, and major depressive disorder. In recognition of his significant contributions to new treatments for mood and anxiety disorders, including the use of ketamine for resistant depression, Charney received the Donald Klein Lifetime Achievement Award from the American Society for Psychopharmacology in 2023.
Neuron published that Charney's neurobiological insights into ketamine are a novel approach to the underlying operation of mechanism-of-action for rapid-acting antidepressant efficacy and mood disorders and is the first model of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. His intranasal ketamine treatment was approved by the FDA in 2019 and now produced under the brand name Spravato. Scientific American published in 2018 that the development is the first new form of antidepressant since the 1950s.
Hub AI
Dennis S. Charney AI simulator
(@Dennis S. Charney_simulator)
Dennis S. Charney
Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #49 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 218 with 173,960 citations across 887 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.
Until July 2025 he was a professor of psychiatry, professor of neuroscience and professor of pharmacology and systems therapeutics at Icahn School of Medicine at Mount Sinai in New York City.
In 2007, he became the Dean of the School and Executive Vice President for Academic Affairs of what was then known as the Mount Sinai Medical Center. In 2013, he was named President of Academic Affairs for the Mount Sinai Health System. He retired as Dean in 2025.
Charney graduated from medical school at Penn State in 1977 and completed his residency in Psychiatry at Yale School of Medicine. A fellowship in Biological Psychiatry was completed at the Connecticut Medical Health Center.
Charney became the dean of research at Mount Sinai School of Medicine in 2004, later becoming the dean for academic and scientific affairs, then succeeding Kenneth L. Davis as dean of the Icahn School of Medicine at Mount Sinai in 2007, retiring in 2025. He was elected to the Institute of Medicine in 2000.
Charney led the Mood and Anxiety Research Program at the National Institute of Mental Health and earlier was on the faculty in the department of psychiatry at Yale Medical School.
According to published works, Charney's research is centered around various fields such as psychiatry, anesthesia, clinical psychology, and major depressive disorder. In recognition of his significant contributions to new treatments for mood and anxiety disorders, including the use of ketamine for resistant depression, Charney received the Donald Klein Lifetime Achievement Award from the American Society for Psychopharmacology in 2023.
Neuron published that Charney's neurobiological insights into ketamine are a novel approach to the underlying operation of mechanism-of-action for rapid-acting antidepressant efficacy and mood disorders and is the first model of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. His intranasal ketamine treatment was approved by the FDA in 2019 and now produced under the brand name Spravato. Scientific American published in 2018 that the development is the first new form of antidepressant since the 1950s.
Recent media